Making it in Manufacturing

ARTO Talent
  • 0.0 (0)
  • Careers
  • Updated Weekly

97% of our listeners don't realise they aren't followed, please double check, thank you! Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series, spotlighting the leaders shaping the future of manufacturing, engineering and CDMOs in Life Sciences. Each episode dives into the careers, decisions, and defining moments of industry mainstays - revealing the stories and insights behind real-world impact within the life science manufacturing and CDMO space. If you're a leader in the space - or aspiring to be - this podcast is a must watch. The series is available on YouTube, Spotify, Apple Podcasts and all major platforms. Hosted on Acast. See acast.com/privacy for more information.

  1. Inside CPHI Americas 2026: The Biggest Challenges Facing Pharma Right Now

    3d ago

    Inside CPHI Americas 2026: The Biggest Challenges Facing Pharma Right Now

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. This week on Making It In Manufacturing, Thomas McMann sat down with Sarah Griffin, Event Manager for CPHI Americas. In this episode, Sarah covers: • Why CPHI Americas is creating a more focused, content-led experience built around meaningful industry conversations and strategic partnerships. • How the event has evolved to meet growing demand for deeper engagement between pharmaceutical companies, CDMOs, technology providers, regulators, and investors. • Why CDMOs are moving from outsourced service providers to long-term strategic partners, with greater transparency, collaboration, and shared risk. • How pharmaceutical companies are balancing supply chain resilience, regionalisation, outsourcing strategies, and operational agility in a changing global market. • What will define the next phase of growth for pharmaceutical services, including advanced therapies, AI integration, talent development, and partnership-driven business models. Be sure to watch this episode if you're attending CPHI Americas to get a complete overview of the agenda and key highlights. Even if you won't be there in person, it's still worth tuning in to stay up to date with the latest CPHI news, announcements, and live event updates. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Sarah Griffin LinkedIn: https://www.linkedin.com/in/sarah-griffin-cem/ Thomas McMann LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 00:00 Introduction 00:48 What makes CPHI Americas different 02:20 Why the event is becoming more content-led 03:25 New features and event changes for this year 04:31 The purpose behind the Hot Seat sessions 05:28 Sarah’s outlook ahead of the event 05:54 How CDMO partnerships are evolving 07:53 Supply chain resilience and outsourcing strategies 09:08 Demand for integrated pharmaceutical services 10:18 What separates successful CDMOs from competitors 12:03 Future growth drivers in pharmaceutical services 13:16 Collaboration and raising industry standards 14:11 What Sarah is most excited about at CPHI Americas 15:23 Sessions Sarah is looking forward to attending 16:23 Quick fire round 16:42 Biggest trend dominating pharma conversations 16:58 Biggest concern for pharma leaders 17:12 What makes CPHI Americas different from other events 17:37 Industry conversations that need more openness 18:09 Closing thoughts #MakingItInManufacturing #ARTOTalent #PharmaceuticalManufacturing #CDMO #PharmaServices #Biologics #CellAndGeneTherapy #SupplyChain #PharmaIndustry #DrugDevelopment Hosted on Acast. See acast.com/privacy for more information.

    19 min
  2. Why End-to-End CDMOs Matter More Than Ever - SmaBio Labs CEO

    May 21

    Why End-to-End CDMOs Matter More Than Ever - SmaBio Labs CEO

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. What does it take to build a CDMO designed around speed, integration, and true scientific collaboration? This week on Making It In Manufacturing, Harry Sloan sat down with LakshmiDevi Ethirajan, Co-Founder & CEO of SmaBioLabs, with 25+ years of experience spanning big pharma, small pharma, and CDMO leadership roles across drug development and manufacturing. In this episode, LakshmiDevi Ethirajan covers: • How a background in pharmacy and pharmaceutical development led to the creation of SmaBioLabs and the vision behind building a fully integrated CDMO • Why bringing discovery, formulation development, and analytical services together under one roof reduces risk and improves program execution • The importance of speed and flexibility in pharmaceutical development, including why projects at SmaBioLabs begin within two weeks of contract signing • How technical integration between discovery scientists and formulation teams supports complex molecules and improves development outcomes • The long-term vision for SmaBioLabs, including commercial manufacturing expansion and becoming a complete end-to-end partner for sponsors If you are involved in pharmaceutical manufacturing, biotech growth, CDMO strategy, or drug development leadership, this conversation offers a practical perspective on building scalable scientific partnerships in a rapidly evolving industry. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent LakshmiDevi Ethirajan Co-Founder & CEO of SmaBioLabs LinkedIn: https://www.linkedin.com/in/lakshmidevi-ethirajan/ Harry Sloan BD CDMO Lead at ARTO LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/ Timestamps: 00:00 Introduction 00:14 LakshmiDevi Ethirajan’s journey into pharmaceuticals 01:07 Why sponsor and CDMO alignment matters 02:27 Building an end-to-end CDMO model 03:58 Speed and flexibility in drug development 05:00 Supporting complex molecules through integration 06:46 The meaning behind the SmaBio Labs name 07:56 Growth plans and commercial manufacturing ambitions 08:51 Standing out in the competitive CDMO market 10:17 The North Carolina biotech ecosystem 12:37 Leadership, culture, and patient impact 13:53 Closing remarks #MakingItInManufacturing #ARTOTalent #CDMO #PharmaceuticalManufacturing #DrugDevelopment #Biotech #LifeSciences #ManufacturingLeadership #PharmaIndustry #Biotechnology #DrugDiscovery #AnalyticalServices #FormulationDevelopment Hosted on Acast. See acast.com/privacy for more information.

    14 min
  3. Why Development-Led CDMOs Will Win

    May 20

    Why Development-Led CDMOs Will Win

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. How do leading CDMOs move beyond manufacturing to become true development partners? In this episode, Jeffrey Speicher shares how integrated development, technical problem solving and long-term partnerships are shaping growth in outsourced pharma manufacturing. This week on Making It In Manufacturing, Harry Sloan sat down with Jeffrey Speicher, General Manager Commercial of PLD Pharma, with over 30 years of experience spanning engineering, commercial leadership, contract manufacturing, OTC product development and strategic growth across the pharmaceutical and consumer healthcare sectors. In this episode, Jeffrey Speicher covers: - How PLDevelopments evolved from a private label manufacturer into a full CDMO model focused on end-to-end support for customers - Why in-house development and commercialisation capabilities help accelerate speed to market and reduce manufacturing risk for pharmaceutical products - The importance of designing formulations around commercial manufacturing equipment from the very beginning of the R&D process - How product diversification across liquids, tablets, electrolytes, and gummies creates broader manufacturing capabilities within the CDMO market - Why partnership-led relationships matter for pharmaceutical brands looking for quality, consistency, and long-term manufacturing support in the US market For anyone operating across CDMO strategy, OTC innovation or outsourced development, this is a thoughtful conversation on what partnership-led manufacturing really looks like. Be sure to check out the full episode for a deeper discussion on leadership, commercial growth and differentiated execution in pharma services. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Jeffrey Speicher General Manager Commercial at PLD Pharma LinkedIn: https://www.linkedin.com/in/jeffrey-speicher-826746/ Harry Sloan CDMO BD Lead at ARTO LinkedIn: https://www.linkedin.com/in/harry-sloan/ Timestamps: 00:00 Introduction 00:21 Jeffrey Speicher introduction and overview of PL Developments 00:45 The origins of PL Developments and private label manufacturing 01:07 Transitioning into a CDMO-focused business model 01:25 What differentiates PL Developments from traditional CDMOs 01:44 The advantages of broad formulation and manufacturing capabilities 02:26 Why upstream development support improves project success 03:05 Connecting R&D with commercial manufacturing equipment 03:37 Speed to market and reducing commercialisation risk 03:55 Competing through partnership and customer focus 04:29 Balancing speed, efficiency, and scalability in manufacturing 05:09 Developing OTC gummies and expanding manufacturing capabilities 05:28 Designing products around plant strengths 05:40 Eliminating risk during commercial transfer 05:44 Closing remarks #MakingItInManufacturing #ARTOTalent #CDMO #PharmaceuticalManufacturing #OTCManufacturing #DrugDevelopment #ContractManufacturing #LifeSciences Hosted on Acast. See acast.com/privacy for more information.

    6 min
  4. The CDMO Framework Winning Business for Adare Pharma Solutions

    May 12

    The CDMO Framework Winning Business for Adare Pharma Solutions

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. The CDMO landscape is crowded, fragmented, and increasingly complex. What does it take to stand out and lead in such a competitive space? This week on Making It In Manufacturing, Harry Sloan sat down with Tom Sellig, CEO of Adare Pharma Solutions with a long-standing career spanning commercial leadership, pharma services, and executive roles across global organisations including, Procter and Gamble, Covance, Patheon, LabConnect, and Thermo Fisher Scientific. In this episode, Tom Sellig covers: - How Adare Pharma Solutions positions itself as a technology-driven oral solid dose CDMO with global capabilities across North America and Europe - Why having both US and European manufacturing capabilities is critical for business continuity, regulatory navigation, and client needs in today’s geopolitical environment - The key differentiators behind Adare’s success, including technological breadth, flexibility as a mid-sized CDMO, and the ability to support both large-scale and highly specialised projects - Building a deeply embedded client-centric culture, including company-wide alignment and continuous customer feedback integration For leaders navigating the CDMO and broader Life Sciences manufacturing space, this episode offers a grounded perspective on strategy, growth, and execution. Watch the full conversation for a clear view on what sustainable leadership in this sector really looks like. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Tom Sellig CEO at Adare Pharma Services LinkedIn: https://www.linkedin.com/in/tomsellig/ Harry Sloan BD CDMO Lead at ARTO LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/ Timestamps: 00:00 Introduction 00:20 Overview of Adare Pharma Solutions 01:05 Importance of global footprint in CDMO services 01:45 Key differentiators in a competitive CDMO market 02:43 Client-centric culture and organisational alignment 03:40 Career journey and leadership development 04:25 Lessons from scaling and acquisitions at Patheon 05:05 The Adare framework and company values 05:57 Future outlook for Adare and the CDMO landscape 07:00 Closing remarks #MakingItInManufacturing #ARTOTalent #CDMO #LifeSciences #PharmaManufacturing #Biopharma #Leadership Hosted on Acast. See acast.com/privacy for more information.

    7 min
  5. Inside the Race to Scale ADCs - Ian Glassford

    May 7

    Inside the Race to Scale ADCs - Ian Glassford

    What does it take to scale complex biologics manufacturing while keeping speed, quality, and communication aligned? In this episode, Ian Glassford explains how integrated CDMO partnerships are helping biotech companies accelerate ADC and bioconjugate programs from discovery through to commercial manufacturing. This week on Making It In Manufacturing, Harry Sloan sat down with Ian Glassford, VP at Abzena, with more than a decade of experience spanning medicinal chemistry, synthetic chemistry, bioconjugation, biologics manufacturing, and CDMO leadership roles across GSK and Abzena. In this episode, Ian Glassford covers: • How Abzena approaches integrated ADC and bioconjugate manufacturing across discovery, development, and GMP production (00:00) • Why communication and true partnership models are becoming critical for CDMOs supporting fast-moving biotech programs (02:55) • The balance between speed to clinic, process standardisation, and maintaining manufacturing quality in complex biologics (03:37) • Ian’s transition from medicinal chemistry at @GSK into leadership within the bioconjugation and ADC space at Abzena (08:11) • Where the future of ADCs, AOCs, radionuclide conjugates, and commercial manufacturing is heading over the next five years (10:25) For anyone working across biologics manufacturing, ADC development, CDMO partnerships, or complex therapeutics, this conversation offers a practical look at how experienced operators are adapting to increasingly demanding timelines and evolving modalities across the biotech industry. Follow ARTO: LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Ian Glassford: LinkedIn: https://www.linkedin.com/in/ian-glassford-phd-mba-28270529/ Harry Sloan: LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/?skipRedirect=true Timestamps: 00:00 Introduction and live recording from DCAT Week in New York 00:39 Ian Glassford explains Abzena’s role in the ADC and bioconjugate CDMO market 01:25 The biggest operational challenges in ADC and AOC manufacturing 02:43 What biotech clients are really looking for beyond technical expertise 03:37 Managing the balance between speed, quality, and execution 04:53 How integrated CDMO and CRO models improve timelines and supply chain control 06:43 The importance of communication and partnership in complex programs 08:11 Ian’s career journey from medicinal chemistry into bio conjugates 10:00 Transitioning from hands-on science into site leadership 10:25 Where Abzena and the wider ADC market are heading in the next five years 11:51 Adapting CDMO models to support evolving biologics modalities 12:29 Closing thoughts #MakingItInManufacturing #ARTOTalent #Biotech #CDMO #Biologics #ADC #DrugDevelopment #Manufacturing #Pharmaceuticals #Bioconjugates Hosted on Acast. See acast.com/privacy for more information.

    13 min
  6. How Samsung Biologics Is Redefining CDMO Partnerships - John Gagliardi

    May 5

    How Samsung Biologics Is Redefining CDMO Partnerships - John Gagliardi

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. How do leading CDMOs move beyond scale to become true strategic partners? This week on Making It In Manufacturing, Harry Sloan sat down with John Gagliardi, Sales Director, Key Account Management at Samsung Biologics, with 25+ years of experience spanning operations, supply chain, procurement, sourcing and commercial leadership across biopharma, including previous experience at GSK and leadership in CDMO partnerships. In this episode, John Gagliardi covers: - How Samsung Biologics has evolved as a pure-play CDMO, including US expansion and the value of integrated support from clinical development through commercial supply. - Why long-term partnerships in biomanufacturing depend on value creation beyond capacity, from lifecycle management to flexible supply chain strategies. - What credible ADC capability really looks like, including integrated manufacturing, simplified supply chains and how co-located operations can accelerate speed to market. - The strategic importance of the Lilly Gateway Labs collaboration with Eli Lilly, and how incubating early-stage biotech can strengthen the future innovation ecosystem. - Where growth is heading next for Samsung Biologics, from Bio Campus expansion and emerging modalities to scaling quality while maintaining operational agility. If you are interested in where biomanufacturing partnerships are heading, and how leading CDMOs are thinking beyond capacity alone, this conversation offers practical insight worth your time. Watch the full episode to hear how John approaches growth, innovation and patient impact through a commercial and operational lens. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent John Gagliardi Sales Director at Samsung Biologics LinkedIn: https://www.linkedin.com/in/john-gagliardi-7a8a252/ Harry Sloan CDMO BD Lead at ARTO LinkedIn: linkedin.com/in/harry-sloan-605620154/?lipi=urn%3Ali%3Apage%3Ad_flagship3_profile_view_base%3B7ieBaX%2FATH6lSPMIPdsI8w%3D%3D Timestamps: 00:00 Introduction from New York and conference spotlight 00:42 Samsung Biologics as a pure-play CDMO 02:10 Building strategic customer partnerships 03:45 Differentiation beyond standard CDMO models 05:01 Building credibility in ADC manufacturing 07:53 Technical collaboration and winning partnerships 09:07 Lilly Gateway Labs collaboration 11:40 Growth trajectory and future modalities 13:19 Scaling while maintaining quality 15:00 Patient impact and personal motivation 16:35 Closing remarks #MakingItInManufacturing #ARTOTalent #Biomanufacturing #CDMO #Biopharma #SupplyChain #ADC #PharmaceuticalManufacturing #BiotechLeadership Hosted on Acast. See acast.com/privacy for more information.

    17 min
  7. We Just Built a $1.5B Biologics Company… And We're Here to Disrupt the Industry - Joon Chang

    Apr 28

    We Just Built a $1.5B Biologics Company… And We're Here to Disrupt the Industry - Joon Chang

    What does it really take to build credibility as a new CDMO in a highly competitive biologics market, while staying grounded in patient impact? This week on Making It In Manufacturing, Harry Sloan sat down with Joon Chang, Chief Business Officer at Lotte Biologics, with years of experience spanning Pharma, CDMO, project management, and business development roles across global organisations. In this episode, Joon Chang covers: • (02:17) Building credibility as a new CDMO and overcoming the challenge of limited track record while leveraging experienced talent from legacy manufacturing sites • (03:05) Why people and expertise matter more than company age when delivering successful tech transfer, development, and manufacturing outcomes • (04:17) The importance of tailoring partnerships to individual client needs and building long-term relationships across Pharma and biotech organisations • (07:00) Career journey from bench scientist to commercial leadership, and how experience across Pharma and CDMO environments shapes client-centric thinking • (10:10) Creating a patient-centric culture in manufacturing and commercial teams, and why connecting daily operations to patient impact strengthens partnerships If you are interested in how emerging CDMOs can differentiate themselves through culture, capability, and client alignment, this episode offers a grounded and practical perspective worth your time. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@life_sciences Joon Chang LinkedIn: https://www.linkedin.com/in/joon-chang-a337895/ Harry Sloan LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/ Timestamps: 00:00 Introduction at the DCAT Conference 00:33 Overview of Lotte Biologics and market positioning 01:20 Capabilities in biologics manufacturing and conjugation 02:01 Challenges of entering the CDMO market as a new player 03:05 Importance of talent and retained expertise from legacy sites 03:52 Building relationships with Pharma and biotech clients 04:24 Dual hub model across the US and South Korea 05:01 Manufacturing scale advantages and commercial readiness 06:19 Speed, cost efficiency, and internal tech transfer benefits 07:00 Career journey from Pharma to CDMO leadership 08:04 Understanding client mindset from both Pharma and CDMO perspectives 08:54 Project management experience and client relationship ownership 09:43 Leadership philosophy and full lifecycle thinking 10:10 Building an ideal organisational culture 10:40 Patient-centric approach and ultra-rare disease considerations 11:43 Connecting operations to patient impact 12:34 Applying culture to commercial and sales teams 13:21 Business development mission and value creation 13:40 Leadership approach and empowering teams 15:00 Vision for disrupting the CDMO industry 16:21 Growth, partnerships, and expanding patient reach 17:01 Personal motivation and purpose behind the work 18:00 Team culture and collaboration #MakingItInManufacturing #ARTOTalent #Biologics #CDMO #Pharma #Biotech #Manufacturing Hosted on Acast. See acast.com/privacy for more information.

    18 min
  8. From Lab Scientist to Pharma Leader: 40 Years of Scaling and Strategy Insight - Alison Clayton

    Apr 23

    From Lab Scientist to Pharma Leader: 40 Years of Scaling and Strategy Insight - Alison Clayton

    From hands-on pharmacology research to leading strategic projects in advanced manufacturing, this episode explores what it really takes to evolve, adapt, and lead across decades of change in life sciences. This week on Making It In Manufacturing, Harry Sloan sat down with Alison Clayton, Strategic Projects Director at Symbiosis, with over 40 years of experience spanning pharmacology research, pre-clinical and clinical development, and pharmaceutical manufacturing. In this episode, Alison Clayton covers: (00:00) Transitioning from academia into industry and navigating major company acquisitions early in a career (01:40) Moving beyond the lab into strategic, customer-facing roles and discovering a passion for leadership (03:35) Adapting to constant organisational change while maintaining a patient-first mindset (07:26) The risks of scaling too quickly in CDMOs and the importance of realistic capacity and strong partnerships (10:02) Maintaining quality and regulatory standards while growing in a highly competitive pharmaceutical landscape This conversation offers a grounded perspective on long-term career development, leadership in complex environments, and the evolving demands of pharmaceutical manufacturing. If you are building a career in life sciences or scaling within a CDMO environment, this episode provides practical insights worth applying. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@life_sciences Alison Clayton LinkedIn: https://www.linkedin.com/in/alison-clayton-78816711/ Harry Sloan LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/ Timestamps: 00:00 Introduction to the episode 00:14 Alison Clayton introduction and career reflection 00:53 Transition from academia to industry 01:15 Experience at Syntex Pharmaceuticals, Roche, and Quintiles 01:40 Moving into strategic and customer-facing roles 02:24 Leadership style shaped by scientific background 02:50 End-to-end experience across drug development 03:13 Navigating challenges and career-defining moments 03:35 Adapting through multiple company transitions 04:24 Balancing commercial goals with patient outcomes 04:56 Experiences in a male-dominated industry 05:51 Advice for women in life sciences leadership 06:09 Career development without a fixed plan 07:00 Balancing career and family life 07:26 Scaling challenges in CDMOs 08:30 Risks of overpromising and underdelivering 09:28 Importance of supply chain and transparency 10:02 Maintaining quality and regulatory compliance 10:27 Overview of Symbiosis 10:57 Market demand for sterile manufacturing 11:20 Scottish identity and company culture 11:39 Differentiation in the CDMO market 12:31 Importance of flexibility and partnerships 13:21 Building long-term client relationships 13:41 Future outlook for Symbiosis 14:05 Evolution of biologics and impact on patients 14:32 Career reflection and delivering medicines to patients 15:17 What excites Alison about the future #MakingItInManufacturing #ARTOTalent #PharmaceuticalManufacturing #LifeSciences #CDMO #Biologics #DrugDevelopment Hosted on Acast. See acast.com/privacy for more information.

    16 min
See All (34)

About

97% of our listeners don't realise they aren't followed, please double check, thank you! Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series, spotlighting the leaders shaping the future of manufacturing, engineering and CDMOs in Life Sciences. Each episode dives into the careers, decisions, and defining moments of industry mainstays - revealing the stories and insights behind real-world impact within the life science manufacturing and CDMO space. If you're a leader in the space - or aspiring to be - this podcast is a must watch. The series is available on YouTube, Spotify, Apple Podcasts and all major platforms. Hosted on Acast. See acast.com/privacy for more information.

Information

You Might Also Like